IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.314
-0.007 (-2.09%)
Apr 28, 2026, 4:00 PM EDT - Market closed
IGC Pharma Revenue
IGC Pharma had revenue of $191.00K in the quarter ending September 30, 2025, a decrease of -53.64%. This brings the company's revenue in the last twelve months to $1.11M, down -6.51% year-over-year. In the fiscal year ending March 31, 2025, IGC Pharma had annual revenue of $1.27M, down -5.50%.
Revenue (ttm)
$1.11M
Revenue Growth
-6.51%
P/S Ratio
28.60
Revenue / Employee
$15,800
Employees
70
Market Cap
30.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.27M | -74.00K | -5.50% |
| Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
| Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
| Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
| Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 40.58M |
| Palatin Technologies | 8.96M |
| Evaxion | 7.53M |
| Dyadic International | 3.09M |
| Pluri | 1.34M |
| Outlook Therapeutics | 205.70K |
| Senti Biosciences | 22.00K |
IGC News
- 9 hours ago - IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase - Accesswire
- 6 days ago - IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion - Accesswire
- 8 days ago - IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia - Accesswire
- 14 days ago - IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout - Accesswire
- 20 days ago - Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts - Accesswire
- 21 days ago - IGC Pharma Adds Tandem Clinical Research to the CALMA Trial for Agitation in Alzheimer's Disease - Accesswire
- 4 weeks ago - IGC Pharma Launches Strategic National Media Partnership with New to The Street to Expand Investor Awareness - Accesswire
- 5 weeks ago - IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 - Accesswire